Exane Derivatives’s KALA BIO KALA Stock Holding History

Exane Derivatives’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6	Closed	-$95.3K	–	953
2020 Q4	$95.3K	Buy	6 +4	+200%	+$75.3K	0.03%	402
2020 Q3	$36.5K	Buy	2 +1	+100%	+$23K	0.01%	392
2020 Q2	$24.9K	Buy	+1	New	+$28.3K	0.01%	393

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Exane Derivatives's KALA Position: Q1 2021 in Review

Exane Derivatives sold out of KALA BIO (KALA) in Q1 2021, closing a stake of 6 shares — an estimated $95.3K sold.

Exane Derivatives first reported a position in KALA in Q2 2020 and held it in 3 quarters. The position peaked at $95.3K in Q4 2020. 106 funds tracked by Wall St. Rank hold KALA as of Q1 2021.

Exane Derivatives reported no remaining KALA BIO position as of Q1 2021 after selling out during the quarter.
Exane Derivatives sold 6 KALA BIO shares in Q1 2021, an estimated $95.3K.
Exane Derivatives first reported a position in KALA BIO in Q2 2020 and held it in 3 quarters.
Exane Derivatives's KALA BIO position peaked at $95.3K in Q4 2020.
106 funds tracked by Wall St. Rank held KALA BIO as of Q1 2021.

Based on Exane Derivatives's 13F filing for Q1 2021, filed 30 Apr 2021.